Veru price to free cash flow VERU

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 489×; May 2021
Peer median: 11.4×

Veru's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2021, at 489×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	489×	489×	489×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	81.4×	77.0×	92.7×
2017	n/m a value too high to mean anything
2016	56.0×	41.6×	72.9×
2015	70.5×	29.2×	88.3×
2014	31.4×	15.4×	316×
2013	21.3×	18.2×	29.8×
2012	20.8×	15.2×	21.2×

Against its peers

Companies in Drug Manufacturers - General nearest Veru's size, closest first, today.

Company	Price to free cash flow
VERUVeru	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
NATRNatures Sunshine Products	11.8×
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Veru

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.